-+ 0.00%
-+ 0.00%
-+ 0.00%

Annovis Bio Says All 84 Facilities For Pivotal Phase 3 Trial In Early Alzheimer's Disease Activated, First Group Of Patients Reaches 6-Month Treatment Milestone

Benzinga·11/06/2025 13:08:36
Listen to the news

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that all 84 sites for its pivotal Phase 3 study in early AD are now fully activated and enrolling participants, with the majority already treating patients across the U.S. This milestone is complemented by another achievement: the first group of patients has completed the 6-month treatment period, keeping the Company on track to deliver symptomatic data in the second half of 2026.